Antibiotic-Free Feed Additive Shows Benefit in Cow Mastitis Trial
Source: Streetwise Reports  (2/24/20)
Avivagen's proprietary product yielded statistically significant results. More >

Healthcare Tech Firm Lands Contract in Florida
Source: Streetwise Reports  (2/22/20)
Reliq Health Technologies will provide the client with two telehealth platforms. More >

Tech Firm Announces New Deals Worth $1 Million
Source: Streetwise Reports  (2/21/20)
These newly signed contracts of HealthSpace Data Systems are with governmental agencies in two U.S. states. More >

Mobile/Telehealth Tech Firm Makes Stock Exchange's Top 10
Source: Streetwise Reports  (2/21/20)
Reliq Health Technologies is chosen based on three criteria. More >

Healthcare Firm Changes Name to Reflect Digital Health and Telemedicine Focus
Source: Streetwise Reports  (2/21/20)
Premier Health Group announced that it changed its name to CloudMD Software & Services Inc., and trading under the symbol DOC will begin Feb. 24. More >

Baudax Shares Rise as FDA Approves NDA for Its Non-Opioid Pain Medication
Source: Streetwise Reports  (2/21/20)
Shares of Baudax Bio traded more than 20% higher and set a new 52-week high price after reporting that the FDA approved the company's non-opioid ANJESOâ„¢ drug for management of moderate to severe pain. More >

FDA Approval of Biopharma's Pain Drug Expected This Year
Source: Streetwise Reports  (2/19/20)
The reasons a green light is anticipated and how it relates to the closing of Avenue Therapeutics' pending acquisition are discussed in an H.C. Wainwright & Co. report. More >

The 'Virus' Technology That Kills Coronavirus Plus Lots of Other Pathogens
Source: Fincom Investment Partners for Streetwise Reports  (2/18/20)
Fincom Investment Partners profiles TOMI Environmental Solutions, whose SteraMist disinfectant technology kills the coronavirus. More >

Viela Bio Shares Trade Higher After Analyst Issues 'Buy' Recommendation
Source: Streetwise Reports  (2/18/20)
Shares of Viela Bio Inc. rose 20% after an analyst at H.C. Wainwright & Co. initiated coverage of the stock. More >

Life Sciences Firm Contracts with Philippines Distributor
Source: Streetwise Reports  (2/18/20)
This agreement will provide another sales channel and additional revenue opportunities for Avivagen's proprietary product. More >

ImmunoGen Shares Rise 25% on FY/19 Financial Results and Clinical Pipeline Updates
Source: Streetwise Reports  (2/14/20)
Shares of ImmunoGen Inc. reached a new 52-week intraday high price after the company announced FY/19 financial results and reported on recent developments including the completion of a $97.6 million capital raise in January 2020. More >

vTv Therapeutics' Shares Open 80% Higher on Phase 2 Type 1 Diabetes Trial Data
Source: Streetwise Reports  (2/10/20)
Shares of vTv Therapeutics traded 50% higher after the company reported positive results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 used in the treatment of patients with type 1 diabetes. More >

Biopharma Has Three 2020 Shots on Goal in Pediatric Liver Diseases
Source: Streetwise Reports  (2/8/20)
The events in that trio are presented in a ROTH Capital Partners report. More >

Telehealth Solutions Firm Gains Further Customer Traction in Texas
Source: Streetwise Reports  (2/7/20)
With the added clients, the company will expand into two more clinical realms. More >

Myriad Genetics Shares Fall 30% on Q2 Earnings and Executive Leadership Change
Source: Streetwise Reports  (2/7/20)
Shares of Myriad Genetics traded 30% lower after the firm released Q2/20 earnings and announced the appointment of a new interim CEO. More >

Cortexyme Secures $125M Private Placement Capital to Advance Clinical Development
Source: Streetwise Reports  (2/6/20)
Shares of Cortexyme Inc. traded 20% higher after the company reported that it secured an additional $125M in capital from a private placement. The firm intends to use the proceeds to fund current Alzheimer's clinical trials and ongoing operations. More >

Vivus Shares Climb 50% Higher on sNDA Approval for Exocrine Pancreatic Insufficiency Drug
Source: Streetwise Reports  (2/5/20)
Shares of Vivus traded higher after the FDA approved the company's supplemental New Drug Application for an improved formulation of PANCREAZE® (pancrelipase) for use in the treatment of exocrine pancreatic insufficiency due to cystic fibrosis and other conditions. More >

Understanding Fortress Biotech
Source: Daniel Carlson for Streetwise Reports  (2/5/20)
Daniel Carlson of Tailwinds Research takes a close look at what he calls a "great value opportunity," with a focus on subsidiary Avenue Therapeutics. More >

MedTech Company Launches Direct to Consumer Telemedicine App
Source: Streetwise Reports  (2/5/20)
The product is initially available to residents of British Columbia. More >

Rapidly Growing Healthcare Tech Firm Appoints President
Source: Streetwise Reports  (2/4/20)
The appointed physician will be tasked with developing global business for the company. More >

Insmed Shares Trade 40% Higher on Phase 2 Top-Line Bronchiectasis Trial Data
Source: Streetwise Reports  (2/3/20)
Insmed Inc.'s shares traded higher today after the company reported positive top-line results from its Phase 2 WILLOW Study of INS1007 in patients with non-cystic fibrosis bronchiectasis. More >

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'
Source: Streetwise Reports  (1/31/20)
The compelling aspects of this life sciences story are presented in a Dawson James report. More >

Syndax Pharma Shares Rise on $35M Capital Raise, Credit Line and Positive Phase 1/2 Leukemia Trial Results
Source: Streetwise Reports  (1/31/20)
Syndax Pharmaceuticals' shares traded 30% higher after the company reported it expects to raise $35 million from a common stock offering from five institutional investors and secured a $30 million non-dilutive term loan facility. More >

CEO Reviews Life Sciences Firm's Year of 'Exceptional Accomplishment'
Source: Streetwise Reports  (1/30/20)
The company makes progress getting its products approved and sold in more countries. More >

Arcadia Ropes in $3 Million in GoodHemp Seed Purchase Orders Within 50 Days of Product Launch
Source: Streetwise Reports  (1/30/20)
Arcadia Biosciences shares traded 25% higher after reporting that it secured $3 million in pre-season GoodHemp seed purchase commitments in just 50 days after launching the product. More >